Parkinson’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson’s Disease market through 2033.

GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which is significantly higher in the US compared to other countries in the 7MM. The 5EU market contributed $674.3 million in sales in 2023, accounting for 20.0% of the global market. Japan contributed sales of $560.4 million in 2023, representing 16.6% of the total global market. GlobalData anticipates that the PD market will grow to be worth approximately $7.9 billion by 2033, at a compound annual growth rate (CAGR) of 8.9%. The US is expected to maintain its position as the market leader in 2033.
Across the 68 markets, sales in the Parkinson’s Disease market were $5.7billion in 2023, growing to $12.4 billion in 2033. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 59.5% and 63.5% of 68-market sales in 2023 and 2033, respectively.

Scope

Overview of Parkinson’s Disease, including epidemiology, symptoms, diagnosis, and disease management.

Annualized Parkinson’s Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Parkinson’s therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Parkinson’s treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global Parkinson’s Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

Current treatments for both early and advanced stage patients focus on controlling the level of dopamine in the brain.

GlobalData’s anticipate that 17 late stage pipeline drugs will launch over the forecast period. These will begin address longstanding unmet needs and are expected to be the main driver of growth in the PD market across the 7MM.

Roche/Prothena’s, a monoclonal antibody, has a novel MOA in the PD market and, if approved, will be revolutionary with potential neuroprotective properties.

The unmet need for therapies for treating late stage complications, such as wearing off, dyskinesia, and psychosis will remain unmet in the 5EU and Japan.

Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM Parkinson’s Disease therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Parkinson’s Disease therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Merz Pharmaceuticals LLC
NeuroDerm Ltd
USB Corp
Newron
Italfarmaco SpA
Kyowa Kirin Co Ltd
Acadia Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Sumitomo Pharma Co Ltd
Otsuka Pharmaceutical Co Ltd
Novartis AG
Eisai Co Ltd
Acorda Therapeutics Inc
Stada Arzneimittel AG
Meiji Co Ltd
Amneal Pharmaceuticals Inc
Alliance Pharma Plc
Britannia Pharmaceuticals Ltd
Annovis Bio Inc
US WorldMeds LLC
Hisamitsu Pharmaceutical Co Inc
Lundbeck LLC
Viatris
Supernus Pharmaceuticals Inc
AbbVie Inc
Prothena Corp Plc
Takeda (Pty) Ltd
Organon
Pharma Two B Ltd
Anavex Life Sciences Corp
Sunovion Pharmaceuticals Asia Pacific Pte Ltd
Meiji Seika Pharma Co Ltd
Alkahest Inc
Teva LLC
Glaxo Smith Kline (GSK)
HLS Therapeutics Inc
Roche
ADAMAS
IRLAB Therapeutics AB
Neuraly Inc
Taiyo Pharma Co Ltd
PureIMS BV
Alora Pharmaceuticals LLC
PharmaTher Holdings Ltd

Table of Contents

List of Contents

List of Tables

List of Figures

1 Executive Summary

1.1 Overview

1.2 68M summary statistics

1.3 Key 7MM events driving the 68M forecast extrapolation

2 Appendix

2.1 Abbreviations

2.2 Methodology

2.2.1 Patient-based forecast methodology

2.2.2 68M forecast extrapolation methodology

2.3 Primary research – key opinion leaders interviewed for this report

2.3.1 Key opinion leaders

2.4 Primary research – prescriber survey

2.5 About the authors

2.5.1 Analyst

2.5.2 Managing analyst

2.5.3 Therapy area directors

2.5.4 Epidemiologist

2.5.5 Epidemiology reviewers

2.5.6 Vice President of Disease Intelligence and Epidemiology

2.5.7 Global Head of Pharma, Research, Analysis and Competitive Intelligence

About GlobalData

Contact Us

Table

Table 1: Parkinson’s Disease: Key Metrics in the 7MM

Table 2: Modified HY Scale of PD Symptoms

Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2008

Table 4: Risk Factors and Comorbidities of PD

Table 5: Treatment Guidelines for PD

Table 6: Parkinson’s Disease Market – Global Drivers and Barriers, 2019-2029

Table 7: Key Events Impacting Sales for Parkinson’s Disease in the US, 2019-2029

Table 8: Parkinson’s Disease Market – Drivers and Barriers in the US, 2019-2029

Table 9: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2019-2029

Table 10: Parkinson’s Disease Market – Drivers and Barriers in the 5EU, 2019-2029

Table 11: Key Events Impacting Sales for PD in Japan, 2019-2029

Table 12: PD Market – Drivers and Barriers in Japan, 2019-2029

Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029

Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 4: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019

Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD

Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging

Figure 7: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019

Figure 8: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019

Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019

Figure 10: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019

Figure 11: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019

Figure 12: Treatment Algorithm for Parkinson’s Patients

Figure 13: Unmet Needs and Opportunities in PD

Figure 14: Pharmacokinetics of Levodopa

Figure 15: Overview of the Development Pipeline in Parkinson’s Disease

Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period

Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period

Figure 18: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Sinemet

Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Requip

Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Nuplazid

Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Azilect

Figure 22: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period (2019-2029)

Figure 23: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029

Figure 24: Sales Forecast by Class for Parkinson’s Disease in the US in 2019 and 2029

Figure 25: Sales Forecast by Class for Parkinson’s Disease in the 5EU in 2019 and 2029

Figure 26: Sales Forecast by Class for PD in Japan in 2019 and 2029

Parkinson’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Parkinson’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Parkinson’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 in real time.

  • Access a live Parkinson’s Disease in 68 Markets – Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.